Company intelligence / Profile preview

Maxygen

Newark / Sunnyvale, California, United Statesmaxygen.com ↗

Ownership: Private
Development stage: Preclinical

Overview

Maxygen offers custom protein engineering services using its proprietary molecular breeding directed evolution platform. The company collaborates with clients to design libraries of protein variants and identify improved proteins for applications such as gene therapy products, more accurate gene editing enzymes, and enhanced biomanufacturing processes. It does not develop or commercialize its own therapeutics.

Modalities: Recombinant proteinProteinEnzyme
Industry: Drug Discovery Services

Drug pipeline

2 assets

MAXY-4

Pre-clinical

Indications: Autoimmune diseases, Transplant rejection

1 more asset in the full pipeline.

Request access →

Beyond the preview

Go deeper on Maxygen.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Maxygen.

Explore the full profile